Anti-CTLA-4 antibodies, especially in combination with other immunotherapies like anti-PD-1/PD-L1, have shown promising results in colorectal cancers with MSI-high (MSI-H) (21). The gene discussed is PDCD1; the disease is colorectal cancer.